FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1866-1868 April 24, 2008 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Nestler, J. E. PubMed Citation

To the Editor: The article by Nestler (Jan. 3 issue)¹ on the use of metformin for the treatment of the polycystic ovary syndrome provides a very good review of the concerns about future diabetes and cardiovascular disease associated with this disorder and with the metabolic syndrome. However, many are unaware of the potential for endometrial disease in patients with the polycystic ovary syndrome.

Since the patient in the vignette shows signs of estrogen breakthrough bleeding, regular progesterone withdrawal bleeding will be required to prevent the development of endometrial disease, including complex hyperplasia and cancer.² Therefore, use of a contraceptive agent . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.